Pharmacokinetic modeling and development of bayesian estimators in kidney transplant patients receiving the tacrolimus once-daily formulation

Therapeutic Drug Monitoring

Volumn 32, Issue 2, 2010, Pages 129-135

  Saint Marcoux, Franck ^a,b   Debord, Jean ^a,b   Undre, Nasrullah ^c   Rousseau, Annick ^a,b,d   Marquet, Pierre ^a,b,d  

^a INSERM   (France)

^b LIMOGES UNIVERSITY HOSPITAL   (France)

^c ASTELLAS PHARMA EUROPE LTD   (United Kingdom)

^d UNIVERSITY OF LIMOGES   (France)

Author keywords

Bayesian estimation; Limited sampling strategy; Tacrolimus; Therapeutic drug monitoring

Indexed keywords

TACROLIMUS;

ACCURACY; ADULT; AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; CLINICAL ARTICLE; CLINICAL PRACTICE; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG MONITORING; FEASIBILITY STUDY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MALE; MODEL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; CHEMICAL MODEL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; GRAFT SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHYSIOLOGY; PROCEDURES; RETROSPECTIVE STUDY;

BAYES THEOREM; CLINICAL TRIALS, PHASE II AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAFT SURVIVAL; HUMANS; KIDNEY TRANSPLANTATION; MALE; MODELS, CHEMICAL; RETROSPECTIVE STUDIES; TACROLIMUS;

EID: 77950191273     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181cc70db     Document Type: Article

References (23)

1. Cross SA, Perry CM. Tacrolimus once-daily formulation: in the prophylaxis of transplant rejection in renal or liver allograft recipients. Drugs. 2007;67:1931-1943.
2. European Medecines Agency. Advagraf: summary of product characteristics. Available at: http://www.emea.europea.eu. Accessed February 2009.
3. Scholten EM, Cremers SC, Schoemaker RC, et al. AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. Kidney Int. 2005;67:2440-2447.
4. Saint-Marcoux F, Knoop C, Debord J, et al. Pharmacokinetic study of tacrolimus in cystic fibrosis and non-cystic fibrosis lung transplant patients and design of Bayesian estimators using limited sampling strategies. Clin Pharmacokinet. 2005;44:1317-1328.
5. Wallemacq P, Armstrong VW, Brunet M, et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European Consensus Conference. Ther Drug Monit. 2009;31:1-14.
6. Debord J, Risco E, Harel M, et al. Application of a gamma model of absorption to oral cyclosporine. Clin Pharmacokinet. 2001;40:375-382.
7. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9:503-512.
8. Astellas Pharma Ltd.Prograf 0.5 mg, 1 mg, 5 mg hard capsules: summary of product characteristics. Available at: http://.emea.europea.eu. Accessed July 2009.
9. Undre NA, van Hooff J, Christiaans M, et al. Low systemic exposure to tacrolimus correlates with acute rejection. Transplant Proc. 1999;31:296-298.
10. Squifflet JP, Backman L, Claesson K, et al. Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients. Transplantation. 2001;72:63-69.
11. Uchida K, Tominaga Y, Haba T, et al. Usefulness of monitoring of AUC(0-4h) during the induction period of immunosuppressive therapy with tacrolimus after renal transplantation. Transplant Proc. 2002;34:1736-1737.
12. Staatz CE, Willis C, Taylor PJ, et al. Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin Pharmacol Ther. 2002;72:660-669.
13. Antignac M, Barrou B, Farinotti R, et al. Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. Br J Clin Pharmacol. 2007;64:750-757.
14. Fukatsu S, Yano I, Igarashi T, et al. Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation. Eur J Clin Pharmacol. 2001;57:479-484.
15. StaatzCE,WillisC,TaylorPJ,etal.Toward better outcomeswithtacrolimus therapy:population pharmacokineticsand individualizeddosage prediction in adult liver transplantation. Liver Transpl. 2003;9:130-137.
16. Antignac M, Hulot JS, Boleslawski E, et al. Population pharmacokinetics of tacrolimus in full liver transplant patients: modelling of the postoperative clearance. Eur J Clin Pharmacol. 2005;61:409-416.
17. Sam WJ, Tham LS, Holmes MJ, et al. Population pharmacokinetics of tacrolimus in whole blood and plasma in Asian liver transplant patients. Clin Pharmacokinet. 2006;45:59-75.
18. Sam WJ, Aw M, Quak SH, et al. Population pharmacokinetics of tacrolimus in Asian paediatric liver transplant patients. Br J Clin Pharmacol. 2000;50:531-541.
19. Staatz CE, Tett SE. Comparison of two population pharmacokinetic programs, NONMEM and P-PHARM, for tacrolimus. Eur J Clin Pharmacol. 2002;58:597-605.
20. Fukudo M, Yano I, Masuda S, et al. Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients. Clin Pharmacol Ther. 2006;80:331-345.
21. Macchi-Andanson M, Charpiat B, Jelliffe RW, et al. Failure of traditional trough levels to predict tacrolimus concentrations. Ther Drug Monit. 2001;23:129-133.
22. Mathew BS, Fleming DH, Jeyaseelan V, et al. A limited sampling strategy for tacrolimus in renal transplant patients. Br J Clin Pharmacol. 2008;66: 467-472.
23. Armendáriz Y, Pou L, Cantarell C, et al. Evaluation of a limited sampling strategy to estimate area under the curve of tacrolimus in adult renal transplant patients. Ther Drug Monit. 2005;27:431-434.